HIMS Retail Traders Flip Bullish After Q2 Print: Hims & Hers Keeps $225M Buyback Ready For Stock ‘Disconnect’
Hims & Hers Health (HIMS) reported Q2 revenue up about 40% to $753M, beating the $730.1M consensus, but adjusted EBITDA fell to $60.3M and it posted an $86M net loss. The company raised 2026 revenue guidance to $3.1B-$3.3B and expects Q3 revenue of $880M-$900M. It said it has $225M unused buyback capacity.
How this was made
The 30-second read
Why it matters
Traders can reprice the stock based on the newly disclosed 2026 and Q3 revenue guidance ranges and the company’s stated ability to repurchase shares when it believes the market price disconnects from intrinsic value.
Market read
A guidance-led repricing catalyst plus capital return optionality, tempered by profitability and cash-flow deterioration details.
What to watch
The $225M buyback is authorization, not execution, and the article notes acquisition, restructuring, and legal costs that may not be fully normalized yet.
Background
The piece frames retail sentiment around Hims & Hers after its Q2 results, emphasizing raised guidance and remaining share repurchase capacity.
Ticker impact
Hims & Hers raised 2026 revenue guidance to $3.1B-$3.3B and Q3 revenue to $880M-$900M, alongside $225M remaining buyback authorization.
Bias toward continued upside attempts in the days after the print, with volatility risk if investors focus on EBITDA decline and cash burn.
The article discloses specific, time-sensitive guidance ranges and capital return capacity, but also highlights EBITDA down, net loss, and negative free cash flow, which can cap follow-through.
Market effects
Telehealth and weight-loss-adjacent platforms may see read-across on demand durability and monetization of GLP-1 access and adjacent therapies.
Primarily US small-to-mid growth sentiment, with limited direct regional spillover implied.
Novo Nordisk Wegovy access commentary could influence broader obesity-treatment distribution narratives, but the article is company-specific.
Counterpoint
The guidance beat may be offset by deteriorating gross margin and falling adjusted EBITDA, with free cash flow still negative, limiting valuation support.
Key entities
- companyHims & Hers Health, Inc.
Telehealth firm reporting Q2 results, raised 2026 revenue and Q3 revenue guidance, and citing $225M remaining buyback authorization.
- companyNovo Nordisk
Referenced as the Wegovy supplier; CEO commentary calls the launch “staggering” and highlights Hims’ platform role.
- companyEucalyptus
Acquired by Hims & Hers with about $225M upfront cash payment, affecting cash and costs.
